Drug Therapy

Olaparib tablet safe in patients with ovarian cancer who received pretreatment

By

A PARP inhibitor in oral tablet form, given in combination with chemotherapy, was deemed safe for heavily pretreated patients with ovarian cancer.

Existing drug offers new hope in a subtype of pancreatic cancer

Existing drug offers new hope in a subtype of pancreatic cancer

By

A new use for an old drug shrinks a particular type of pancreatic cancer and stops it from spreading, according to new research.

Some aggressive cancers may respond to anti-inflammatory drugs

By

New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs currently used to treat rheumatoid arthritis.

Skin gel helps fight against breast cancer

Skin gel helps fight against breast cancer

A gel containing the drug tamoxifen and applied to the skin was as effective as the pill form in reducing the growth of breast cancer cells in women with noninvasive cancer.

Nanoliposome formulation improves drug delivery and survival in metastatic pancreatic cancer

By

The addition of MM-398, a novel nanoliposome formulation of irinotecan, to standard treatment improves survival for metastatic pancreatic cancer patients who have already received gemcitabine.

Combination treatment improves recurrence and survival in ovarian cancer

By

A new combination of medications for treatment of recurrent ovarian cancer showed improved response rates, increased the rate of tumor shrinkage, and prolonged the time until cancers recurred

Engineered Nanoparticles Prevent Bone Cancer, Strengthen Bones

Engineered Nanoparticles Prevent Bone Cancer, Strengthen Bones

Nanomedicine technologies were utilized to develop a drug-delivery system that precisely targets and attacks cancer cells in the bone. It also increases bone strength and volume to prevent bone cancer progression.

Novel drug combination may help patients with follicular lymphoma

By

A high-risk group of patients with follicular lymphoma could benefit from a novel drug combination, according to a new study published in the Journal of Experimental Medicine.

Unique experiment aims to rapidly test lung cancer drugs

Unique experiment aims to rapidly test lung cancer drugs

Five drug companies, the government, private foundations, and advocacy groups have come together to try a bold new way for testing cancer drugs. Described as a medical version of speed dating, physicians will sort through multiple experimental drugs and match patients to the one most likely to succeed.

Study Shows Older Patients With Breast Cancer Patients Do Follow Drug Therapy

Study Shows Older Patients With Breast Cancer Patients Do Follow Drug Therapy

Many older breast cancer patients with localized disease are taking drug treatments to prevent their cancer from returning, a new study finds. The research, covering a 7-year period, included more than 1,000 women, age 65 to 91 years, across the United States who had estrogen-positive breast cancer that had not spread.

Nearly one-quarter of children in remission from ALL miss doses of maintenance medication

Nearly one-quarter of children in remission from ALL miss doses of maintenance medication

Children in remission from acute lymphocytic leukemia (ALL) must take 6-mercaptopurine (6MP) for 2 years to prevent disease reemergence; however, a study shows that an estimated 25% of children in remission are not taking this essential maintenance medication at least 90% of the time, tripling their relapse risk.

Resistance to ibrutinib in chronic lymphocytic leukemia explained

Resistance to ibrutinib in chronic lymphocytic leukemia explained

By

A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia.

PD-L1 protein levels predict response to immunotherapy in lung cancer patients

By

Among patients with non-small cell lung cancer treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes.

Early promise against melanoma from new antibody-drug conjugate

By

The investigational drug DEDN6525A, a new antibody-drug conjugate, was safe, tolerable, and showed hints of activity against three forms of melanoma: cutaneous, mucosal, and ocular.

Subset of patients with breast cancer patients will most likely benefit from neratinib

By

The I-SPY 2 trial identified a neo-adjuvant regimen containing the investigational drug neratinib and standard chemotherapy to be beneficial for HR-negative, HER2-positive primary (nonmetastatic) breast cancer patients.

Cause of resistance to PI3K-alpha inhibitor identified

By

In women with breast cancer, loss of the tumor suppressor PTEN was a frequent cause of resistance to the investigational drug BYL719, which blocks the activity of a protein called PI3K-alpha.

Adult cancer drug offers hope against aggressive pediatric brain tumor

By

The quest to improve survival of children with a high-risk brain tumor has led investigators to two drugs already used to treat adults with breast, pancreatic, lung, and other cancers.

New drug successful against crizotinib-resistant, ALK-positive lung cancer

By

A new drug, ceritinib, appears to be effective against advanced ALK-positive non-small cell lung cancer, both in tumors that have become resistant to crizotinib and in those never treated with the older drug.

Exceptional response to everolimus is reported in patient with bladder cancer patient

By

A patient with advanced bladder cancer experienced a complete response to the drug combination everolimus and pazopanib in a phase 1 clinical trial. Genomic profiling revealed information that could help identify other patients who may respond to everolimus and pazopanib.

Experts praise drug trial for building a realistic study population

By

A German study of a new drug therapy for chronic lymphocytic leukemia (CLL) was lauded for including elderly persons who had other, coexisting health issues. An accompanying editorial noted that the study population more accurately represented patients with CLL.

Advocating for treatment of anticipatory reactions

Advocating for treatment of anticipatory reactions

By

What can nurses do to advocate for the use of medications such as lorezepam (Ativan) for anticipatory nausea when the physician is reluctant to prescribe antianxiety or sleep medications?

Bone turnover markers predict prostate cancer outcomes

Bone turnover markers predict prostate cancer outcomes

By

Biomarkers for the formation and resorption of bone predict outcomes for men with castration-resistant prostate cancer (CRPC).

Investigational drug may increase survival of advanced melanoma

By

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to an early-phase clinical trial.

Patient requests affect clinician prescribing behavior

Patient requests affect clinician prescribing behavior

Patients requesting specific medications are more likely to be prescribed those medications, according to research.

Antipsychotic medications offer hope against glioblastoma

By

Researchers have discovered that FDA-approved antipsychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma.

Malaria drug may help overcome resistance to melanoma BRAF drugs

By

A never-before-seen autophagy mechanism induced by the BRAF inhibitors vemurafenib and dabrafenib explains the resistance that melanoma develops to these BRAF inhibitors, according to new research.

Advanced approach invented to ID drug candidates from genome sequence

By

In research that could ultimately lead to many new medicines, scientists have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.

Potential therapy for rare, drug-resistant GISTs

By

By screening a library of US FDA-approved anticancer drugs that previously wouldn't have been considered as a treatment for a rare type of cancer, scientists were surprised to find several potential possibilities.

Out-of-pocket costs influence adherence to treatment

Out-of-pocket costs influence adherence to treatment

Many patients skip doses or stop taking medication entirely when their share of the costs becomes too high.

TCGA study of bladder cancer reveals potential drug targets

TCGA study of bladder cancer reveals potential drug targets

By

Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified new potential therapeutic targets for a major form of bladder cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs